C3 Recombinant Monoclonal Antibody

Code: CSB-RA355590MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P01024

Target Names

Alternative Names

ASP antibody; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody; C3 antibody; C3adesArg antibody; C3bc antibody; CO3_HUMAN antibody; Complement C3c alpha'' chain fragment 2 antibody

Species Reactivity

Human

Immunogen

Recombinant Human C3 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

7F6

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Overlay Peak curve showing HepG2 cells stained with CSB-RA355590MA1HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was Fluorescein (FITC) AffiniPure Goat Anti-Human IgG, Fcγ fragment specific at 1:200 dilution for 35min at 4℃.Control antibody (green line) was human IgG1 (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

Complement C3 stands as the central component of the complement system, playing a pivotal role in both innate immunity and inflammatory responses. Upon activation, C3 undergoes proteolytic cleavage to generate biologically active fragments including C3a and C3b, which mediate diverse functions from opsonization and phagocytosis to immune cell recruitment. Dysregulation of C3 has been implicated in numerous pathological conditions, including autoimmune disorders, age-related macular degeneration, and various inflammatory diseases, making it a compelling target for immunological and disease-focused research.

This recombinant monoclonal antibody, clone 7F6, offers the reproducibility and consistency that demanding experimental workflows require. Developed using recombinant technology with a defined human IgG1 framework, this antibody eliminates the lot-to-lot variability inherent in traditional hybridoma-derived reagents. The sequence-defined nature ensures that researchers can confidently compare results across extended studies and between laboratories.

Validated for flow cytometry applications, this antibody has demonstrated reliable performance in intracellular staining of HepG2 cells, a human hepatocellular carcinoma line known to express complement components. Flow cytometry validation employed cells fixed with formaldehyde and permeabilized with Triton X-100, with recommended working dilutions ranging from 1:50 to 1:200. The antibody is also suitable for ELISA-based detection methods, providing flexibility across different experimental platforms.

Supplied in a stabilized liquid format containing glycerol and PBS, this antibody is ready for immediate use in complement biology studies, liver disease research, and investigations into inflammatory pathways where C3 function is of interest.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.; Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.; Acts as a chemoattractant for neutrophils in chronic inflammation.; adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2.

Gene References into Functions

Evasion of C3b deposition at division septa and lateral amplification underneath the capsule requires localization of the FH-binding protein PspC at division sites. PMID:30139996
Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. PMID:29695177
In our meta-analysis, C3 genetic polymorphisms unveiled a positive effect on the risk of advanced age-related macular degeneration, especially in Caucasians PMID:30352574
Case Report: recurrent proliferative glomerulonephritis with persistent isolated C3 deposition. PMID:29968411
A phage Ab against C3b that inhibited the alternative complement pathway, but not the classical pathway, was described in 2009. Studies using this Ab in a variety of assays have now demonstrated that it acts primarily by inhibiting tickover, thereby confirming that tickover really exists. PMID:28855277
Anti-HLA class I and class II C3d-binding donor-specific antibodies carried a twofold and 1.5-fold increased risk of kidney graft loss, respectively. PMID:29265514
Study shows no significant association of the C3 gene with uveitis, suggesting C3 confers either no or limited risk for uveitis susceptibility. PMID:28408754
Here we have shown for the first time, that ligand- or insulin-mediated activation of PPARgamma in human hepatoma cell line HepG2 causes the downregulation of C3 gene expression and protein secretion PMID:29550264
Single Nucleotide Polymorphism rs11569514 in C3 and haplotypes of C3 variants were associated with schizophrenia in a Han Chinese population. PMID:29742493
alphaXbeta2 uses the alphaX alphaI domain to bind iC3b on its C3c moiety at one of two sites. PMID:28292891
findings revealed a significant association between variant p.R102G in complement component C3 gene with exudative age-related macular degeneration in the Tunisian population PMID:28470643
SNPs within the complement genes may contribute to IA, the first step to type 1 diabetes, with at least one SNP in C3 significantly associated with clinically diagnosed type 1 diabetes. PMID:27306948
An increase in serum C4, as well as a decrease in C3, was an important outcome determinant for patients with immunoglobulin A nephropathy. PMID:28697742
rituximab was not effective in few cases of complement-mediated C3 glomerulonephritis and dense deposit disease . Despite promising results in immunoglobulin-associated and idiopathic Membranoproliferative glomerulonephritis, current evidence on this treatment remains weak, and controlled and prospective data are urgently needed. PMID:28573137
C3F polymorphism is associated with viral infections and protection from rejection after liver transplantation. PMID:27801525
Pra1 targets C3 by cleaving C3 at a unique site. This inhibited effector function of the activation fragments. The newly formed C3a-like peptide lacked the C-terminal arginine residue needed for C3a-receptor binding and activation. Pra1 also bound to C3a and C3b generated by human convertases and blocked their effector functions, C3a binding to human C3a receptor, C3 antifungal activity, and C3b deposition. PMID:28860090
data provide the first evidence that T17M rhodopsin mutant disrupts C3 secretion via the induction of ROS and the suppression of TWIST1. PMID:28569420
High C3 was significantly associated with incidence of diabetes after risk factor adjustments PMID:29029276
This study enclosed strong synergistic association of risk genotypes of C3 and CFH Y402H with AMD. We also revealed synergistic influence of CCL2-2518 and the at-risk genotype of the C3 in AMD with an estimated AP = 50.9% (adjusted AP = 24.7%). Present findings show that CCL2-2518 polymorphism is not an innocent bystander in AMD susceptibility when combined with the at-risk genotype of C3 (R102G). PMID:28095095
Our study shows C3 to be a relatively strong susceptibility gene for advanced-type-AMD (exudative-and-geographic-atrophy) in an Iranian population. PMID:27029644
BBB disruption is present in ACS, and elevated levels of IL-6 and C3 in CSF in diffuse NPSLE PMID:29036223
mobilizes dental pulp stem cells and specifically guides pulp fibroblast recruitment PMID:27497510
This study uncovers the origin of the effect of ionic strength on C3d-CR2 interaction and deepens the understanding of the molecular mechanism of their interaction, which is valuable for the design of vaccines and small molecule inhibitors. PMID:27154286
Studies indicate that the complement response lie the active fragments, C3a and C5a, acting through their specific receptors, C3aR, C5aR1 and C5aR2 to direct the cellular response to inflammation. PMID:28576324
Plasma C3b levels are significantly increased in thrombotic microangiopathy patients after allogeneic stem cell transplantation. PMID:28801815
Findings indicate that recognition of C3-opsonized Francisella tularensis, but not extensive cytosolic replication, plays an important role in regulating macrophage viability during intracellular infections with type A F. tularensis. PMID:28739830
exposure of neural stem cells to neutrophil-synthesized concentrations of C1q and C3a promoted astrogliogenesis and cell migrationtion. PMID:28687659
THP appears to participate directly in complement inactivation by its ability to act as a cofactor for C3b degradation. PMID:28742158
These data suggest that locally produced C3 is an important prosurvival mechanism in pancreatic beta-cells under a proinflammatory assault. PMID:28582497
many types of human cells specifically internalized C3(H2O), the hydrolytic product of C3, and not native C3, from the extracellular milieu. PMID:28192370
Decreased C5a expression is associated with increased inflammation in cystic fibrosis. PMID:28278205
Results show that expression of C3 was significantly increased in tumors from patients having a poor response to chemoradiation therapy. PMID:27254108
C3d-positive glomerular staining is an independent risk factor for the development of end-stage renal disease in ANCA-associated renal vasculitis. PMID:27257040
Factor I binds C3b-Factor H between Factor H domains 2 and 3 and a reoriented C3b C-terminal domain and docks onto the first scissile bond, while stabilizing its catalytic domain for proteolytic activity. PMID:28671664
The VEGF haplotype TGA could be used as a marker for poor visual prognosis in Tunisian patients with neovascular AMD treated with bevacizumab. PMID:27116510
C3 SNP rs2277984 may be a potential biomarker for predicting metabolic syndrome risk in patients receiving clozapine treatment. PMID:26503818
Strikingly C3, the central component of complement, plays a crucial role in the adherence of Brugia malayi to vascular endothelial cells. PMID:28481947
The uromodulin-CFH interaction enhanced the cofactor activity of CFH for factor I-mediated cleavage of C3b to inactivated C3b. PMID:27113631
Generated monoclonal antibody that can only bind to C3d when it manifests itself as the final end product of cleaved C3. PMID:28174050
C3 was strongly associated with insulin sensitivity after bariatric surgery. PMID:28188738
Study reveals structural differences and similarities between C3(H2O), its progenitor C3, and its functional analogue C3b. Data suggest that C3(H2O) generation is accompanied by the migration of the thioester-containing domain of C3 from one end of the molecule to the other. PMID:27250206
human neutrophil peptides 1-3 and complement activation fragments iC3b were higher in patients with acute thrombotic thrombocytopenic purpura - indicating a role of innate immunity in acute autoimmune TTP. PMID:27662014
The data suggest a common evolutionary origin for both inhibitory mechanisms, called decay acceleration and cofactor activity, with variable C3b binding through domains at sites ii, iii, and iv, and provide a framework for understanding regulators of complement activation (RCA) disease-related mutations and immune evasion. PMID:27013439
CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in Comparison of Age-Related Macular Degeneration Treatments Trials . PMID:27099955
Elevated C3a is able to predict the mortality following cardiac resynchronization therapy of heart failure PMID:27492980
Decreased serum C3 may have a role in renal pathology classification for patients with silent but not with overt lupus nephritis PMID:27900491
Decreased transcription of C3R mRNA was found in patients with Type 2 Diabetes as compared to non-diabetics. PMID:27291248
analyzed C5 c.2654G>A and C3 gene polymorphism in 220 Chinese patients PMID:27307199
this paper shows that chymase may control C3-related pathology in cutaneous vasculitis PMID:27465068
Case Report: severe active C3 glomerulonephritis triggered by immune complexes treated with eculizumab. PMID:27717365

Hide All

Subcellular Location

Secreted.

Tissue Specificity

Plasma. The acylation stimulating protein (ASP) is expressed in adipocytes and released into the plasma during both the fasting and postprandial periods.

Database Links

HGNC: 1318

UNIGENE: Hs.529053

KEGG: hsa:718

STRING: 9606.ENSP00000245907

OMIM: 120700

Promotions